ChemicalBook >> journal list >> Cancers >>article
Cancers

Cancers

IF: 4.4
Download PDF

TIGD1 Function as a Potential Cuproptosis Regulator Following a Novel Cuproptosis-Related Gene Risk Signature in Colorectal Cancer

Published:13 April 2023 DOI: 10.3390/cancers15082286 PMID: 37190215
Zhiwei Wu, Changwei Lin, Fan Zhang, Zhixing Lu, Yaohui Wang, Yang Liu, Zhijiao Zhou, Liang Li, Liying Song

Abstract

Cuproptosis is a new form of copper-dependent programmed cell death commonly occurring within the body. There is emerging evidence indicating that cuproptosis has a significant regulatory function in the onset and progression of cancer. However, it is still unclear how cuproptosis regulates cancer and whether other genes are involved in the regulation. Using the TCGA-COAD dataset of 512 samples, we found that seven of ten cuproptosis markers showed prognostic value in colorectal cancer (CRC) using Kaplan-Meier survival analysis. Furthermore, 31 prognostic cuproptosis-related genes were identified using weighted gene co-expression network analysis and univariate Cox analysis. Subsequently, we constructed a 7-PCRG signature using least absolute shrinkage and selection operator (LASSO)-Cox regression analysis. The risk score predicting survival in patients with CRC was evaluated. Two risk groups were classified based on their risk scores. The two groups revealed a significant difference in immune cells, such as B and T cells. Furthermore, we identified differences in many immune functions and checkpoints, including CD276 and CD28. In vitro experiments showed that a hub cuproptosis-related gene, TIGD1, could significantly regulate cuproptosis in CRC after exposure to elesclomol. This study validated that cuproptosis was closely related to the progression of CRC. Seven new cuproptosis-related genes were identified, and the function of TIGD1 in cuproptosis was preliminarily understood. Since a certain concentration of copper in CRC cells is important, cuproptosis may provide a new target for cancer therapy. This study may provide novel insights into the treatment of CRC.

Substances (12)

Materials
Procduct Name CAS Molecular Formula Supplier Price
3-METHYLADENINE 5142-23-4 C6H7N5 396 suppliers $20.00-$1890.00
3-METHYLADENINE 5142-23-4 C6H7N5 396 suppliers $20.00-$1890.00
Necrostatin-1 4311-88-0 C13H13N3OS 256 suppliers $26.00-$2000.00
Necrostatin-1 4311-88-0 C13H13N3OS 256 suppliers $26.00-$2000.00
Ferrostatin-1 (Fer-1) 347174-05-4 C15H22N2O2 246 suppliers $10.00-$1468.50
Ferrostatin-1 (Fer-1) 347174-05-4 C15H22N2O2 246 suppliers $10.00-$1468.50
Elesclomol 488832-69-5 C19H20N4O2S2 177 suppliers Inquiry
Elesclomol 488832-69-5 C19H20N4O2S2 177 suppliers Inquiry
Q-VD-OPh hydrate 1135695-98-5 C26H25F2N3O6 136 suppliers $28.00-$2500.00
Q-VD-OPh hydrate 1135695-98-5 C26H25F2N3O6 136 suppliers $28.00-$2500.00

Similar articles

IF:4.6

Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer.

iScience Xu Yang, Li Deng,etc Published: 16 October 2023
IF:3

MiR-23a-3p targets PTEN as a novel anti-ferroptosis regulator in Fuchs endothelial corneal dystrophy

Experimental eye research Miaomiao Chi, Yaning Zhao,etc Published: 22 November 2024
IF:5.3

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

ACS Applied Nano Materials Jennifer Ferris, Margarita Espona-Fiedler,etc Published: 21 July 2020